Insmed, Inc. INSM

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

• Zacks Investment Research 1 oct

  Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

  A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

  

• Zacks Investment Research 22 sept

  FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

  Insmed announced FDA acceptance of a regulatory filing for Arikayce label expansion to treat newly diagnosed MAC lung disease patients. The FDA granted priority review with a decision expected by January 28, 2027. Arikayce sales grew 7% to $214.4 million in H1 2026, with full-year expectations of $450-470 million. The label expansion could significantly increase the addressable market from 30,000 to over 200,000 patients.

  

• Zacks Investment Research 11 sept

  LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

  Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.

  

• GlobeNewswire Inc. 31 ago

  Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

  The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.

  

• Zacks Investment Research 31 ago

  Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

  Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.